Serum IL-17 Correlated With Inflammatory Changes in Osteoarthritis and Rheumatoid Arthritis

Serum IL-17 Correlated With Inflammatory Changes But Not With Bony Changes in Both Hand Osteoarthritis and Rheumatoid Arthritis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04474912

Enrollment

120

Registered

2020-07-17

Start date

2020-07-01

Completion date

2020-11-29

Last updated

2023-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis (RA) and Osteoarthritis (OA)

Brief summary

The total number of the included subjects was 120 in 3 equal groups (RA, OA and control). All subject was subjected to serum IL17 level measurement. MSK US (of both wrists, MCPs, PIPs and DIPs) was done to all patients in RA and OA groups. Disease activity was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* A patient is considered having definite RA if he/she scores at least 6 points in the established classification system * A patient is considered having Hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands

Exclusion criteria

* Any subject with liver diseases, coronary artery diseases, kidney diseases or other inflammatory conditions was excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
Clinical disease activity in Rheumatoid Arthritis (RA) and hand Osteoarthritis (OA) patients	12 months	During the whole course of the study, disease activity of the patients was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients.

Secondary

Measure	Time frame	Description
IL-17 serum levels in RA and OA patients	2 weeks	IL-17 will be measured by enzyme linked immunosorbent assay from collected serum samples from the study participants

Other

Measure	Time frame	Description
Radiologic bony changes in RA and OA patients	12 months	During the whole course of the study period, recruited participants undergone musculoskeletal (MSK) ultrasound to assess the bony changes.

Countries

Egypt

Outcome results